Lonza Group AG logo

Lonza Group AG (LONN)

Market Closed
12 Jun, 15:30
XWBO XWBO
531. 80
-2.2
-0.412%
- Market Cap
57.91 P/E Ratio
4.57% Div Yield
0 Volume
0 Eps
534
Previous Close
Add Transaction
Day Range
531 542.6
Year Range
499.6 633.6
Want to track LONN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LONN closed today lower at €531.8, a decrease of -0.412% from yesterday's close, completing a monthly decrease of -2.0987% or -€11.4. Over the past 12 months, LONN stock lost -8.8447%.
LONN pays dividends to its shareholders, with the most recent payment made on May 19, 2026.
The last earnings report, released on Apr 16, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Lonza Group AG has completed 2 stock splits, with the recent split occurring on May 02, 2017.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on SIX (CHF).

LONN Chart

Lonza Group AG (LONN) FAQ

What is the stock price today?

The current price is €531.80.

On which exchange is it traded?

Lonza Group AG is listed on XWBO.

What is its stock symbol?

The ticker symbol is LONN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.57%.

What is its market cap?

As of today, no market cap data is available.

Has Lonza Group AG ever had a stock split?

Lonza Group AG had 2 splits and the recent split was on May 02, 2017.

Lonza Group AG Profile

Professional Services Industry
Industrials Sector
Wolfgang Wienand CEO
XWBO Exchange
CH0013841017 ISIN
CH Country
17,995 Employees
12 May 2026 Last Dividend
2 May 2017 Last Split
- IPO Date

Overview

Lonza Group AG is a global leader in providing a wide array of products and services across the pharmaceutical, biotech, and nutrition markets. With a rich history dating back to 1897, Lonza has established a substantial presence across Europe, North and Central America, Latin America, Asia, Australia, and New Zealand. Its operations are categorized into four main segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Each of these segments plays a crucial role in Lonza’s efforts to support the healthcare and nutritional industries, ensuring that the company remains at the forefront of contract development and manufacturing services. Headquartered in Basel, Switzerland, Lonza is committed to driving innovation and excellence in the life sciences and nutrition sectors worldwide.

Products and Services

  • Biologics
  • Lonza’s Biologics segment specializes in the contract development and manufacturing of biopharmaceuticals, covering both clinical and commercial manufacturing needs across the entire product lifecycle. This includes both drug substance and drug product manufacturing, catering to a wide range of biopharmaceutical companies seeking reliable and comprehensive manufacturing solutions.

  • Small Molecules
  • As an integrated service provider, the Small Molecules segment supports the development and manufacturing of small molecule drug substances and their intermediates. Lonza offers services across design, development, and manufacturing, which include particle engineering and drug product packaging. This segment addresses the needs of customers looking for end-to-end solutions in small molecule drug development.

  • Cell & Gene
  • This segment is dedicated to developing technologies and platforms that standardize the production processes of cell and gene therapies. It offers contract development and manufacturing services along with regulatory support for a variety of cell therapies (both allogeneic and autologous) and viral vector gene therapies. Key offerings also include the Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing, and specialty raw materials for the biomanufacturing market.

  • Capsules & Health Ingredients
  • Lonza’s Capsules & Health Ingredients segment caters to pharmaceutical and nutraceutical customers, offering capsules, dosage form solutions, and health ingredients. This segment leverages Lonza’s expertise in capsule technologies and nutritional ingredients to support the development and delivery of effective health and wellness products.

Contact Information

Address: Muenchensteinerstrasse 38
Phone: 41 61 316 81 11